drugset / Trial / NCT01863953

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

NCT01863953

Phase 2 Completed 112 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.

Timeline

Start
2013-06
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bimatoprost Other / unclassified 0.01 % Other
Comparator Brimonidine Small molecule 0.2 % Other